Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19

Description of the Study:

  • Title: Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19.
  • Principal Investigator: Jose Manuel Lomas.
  • Center of Implementation: Hospital Universitario Virgen del Rocio.
  • Study Population: 40 individuals ≥ 18 years of age infected with SARS-CoV-2 and hospitalized or emergency inpatient.
  • Study Type: Phase II national single-center clinical trial.
  • Design: Proof-of-concept trial evaluating standard treatment together with Maraviroc compared to treatment alone.
  • Methods:
    – The experimental group is administered the drug Maraviroc orally daily for 14 days in combination with standard treatment.
    – The standard treatment group is based on the COVID-19 inpatient treatment protocol and will depend on the clinical condition of the patient.

Objectives of the Study:

Principal Objective: To evaluate the safety and efficacy of Maraviroc combined with standard therapy versus standard therapy in relation to clinical progression of COVID-19 in hospitalized patients.

Secondary Objectives:
(1) To analyze changes in analytical variables related to the progression of COVID-19.
(2) To study variation in biomarkers of inflammation.
(3) To analyze changes in innate (monocytes and dendritic cells) and adaptive (T lymphocytes) immune activation.

More about this Study:

Maraviroc is a drug very well tolerated which has been shown to have immune modulating properties, exerting an anti-inflammatory effect in different diseases. In COVID-19 there are very high levels of inflammation that cause damage to organs and systems. This drug could reduce this inflammation leading to a better prognosis of COVID-19.


Other Clinical Trials:

Un bain de bouche antiviral et COVID-19

L'utilisation d'un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2…

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l'évolution de la réponse immunitaire dans les mois qui suivent l'infection par le SARS-CoV-2 chez les hommes…

COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d'une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l'air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…


Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of…

Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of…

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer's COVID vaccine in children under 12 years of age.